Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNX-1000
- Development stage
- Unknown
- Lead developer
- Dynamix Pharmaceuticals
- Modality
- Small Molecules
01
Overview
DNX-1000 is a small molecule inhibitor of Polo-like kinase 1 (PLK1) developed by Dynamix Pharmaceuticals. PLK1 is a serine/threonine kinase that serves as a master regulator of the cell cycle, particularly during the transition into and through mitosis. By selectively inhibiting PLK1, DNX-1000 disrupts centrosome maturation, spindle formation, and chromosome segregation, leading to mitotic catastrophe and apoptosis in cancer cells. The compound is designed to target the high mitotic index of malignant cells while potentially offering a therapeutic window over normal tissues. It is currently in Phase 1 development for the treatment of advanced cancers, including solid tumors and hematological malignancies.
Beyond the preview
Go deeper on DNX-1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNX-1000.